Palabras clave
Insuficiencia renal crónica
Farmacovigilancia
Efectos adversos a largo plazo
Nefritis intersticial
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Investigar la literatura científica relacionada con la asociación entre el uso prolongado de inhibidores de la bomba de protones (IBP) y el riesgo de enfermedad renal. Métodos: Se trata de una revisión integradora de la literatura de artículos publicados entre 2019 y 2024, en portugués o inglés y con texto completo libre. Se utilizó la pregunta orientadora: ¿Cuál es la relación entre el uso prolongado de IBP y el mayor riesgo de enfermedad renal? La investigación se realizó en diciembre de 2024, en las bases de datos de la Biblioteca Virtual en Salud (BVS), SciELO, PUBMED y LILACS, a través de los Descriptores en Ciencias de la Salud (DeCS): Inhibidores de la Bomba de Protones, Insuficiencia Renal Crónica, Farmacovigilancia, Adversos a Largo Plazo. Efectos y Nefritis Intersticial asociados al operador booleano “Y”. Resultados: 23 artículos cumplieron con los criterios de inclusión y exclusión, en los que el riesgo de desarrollar enfermedades renales se asocia con el uso prolongado de IBP. Consideraciones finales: Los IBP son eficaces en el tratamiento de afecciones gastrointestinales, pero su uso prolongado se asocia con eventos adversos. El uso sensato y el seguimiento continuo son esenciales para reducir los riesgos. Sin embargo, la escasez de estudios longitudinales y la variabilidad en los métodos de monitorización renal dificultan la generalización de los resultados.
Referencias
BEN-ELTRIKI M, et al. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence. Pharmacology Research and Perspectives, 2020; 8(5).
BHATNAGAR MS, et al. Long-term use of proton-pump inhibitors: Unravelling the safety puzzle. Cureus, 2024; 16(1): e23334.
BONGERS F, et al. A importância da formação de enfermeiros e da qualidade dos serviços de saúde. Revista Eletrônica Acervo Enfermagem, 2018; 1: 1-8.
CASTELLANA C, et al. Side effects of long-term use of proton pump inhibitors: Practical considerations. Polish Archives of Internal Medicine, 2021; 131(6): 541–549.
CHOLIN L. Do proton-pump inhibitors cause CKD and progression of CKD?: CON. Kidney360, 2022; 3(7): 1137–1140
CHINZON D, et al. Safety of long-term proton pump inhibitors: facts and myths. Arquivos de Gastroenterologia, 2022; 59(2): 219–225.
OLIVEIRA GK, et al. O uso do omeprazol: uma avaliação dos efeitos da administração prolongada do medicamento. Revista Eletrônica Acervo Saúde, 2018.
EDINOFF AN, et al. Proton pump inhibitors, kidney damage, and mortality: an updated narrative review. Advances in Therapy, 2023; 40(6): 2693–2709.
EUSEBI LH, et al. Proton pump inhibitors: risks of long-term use. Journal of Gastroenterology and Hepatology, 2017; 32(7): 1295–1302.
FOSSMARK R, et al. Adverse effects of proton pump inhibitors—evidence and plausibility. International Journal of Molecular Sciences, 2019; 20(20).
HAASSTRUP PF, et al. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterology, 2021; 8(1).
IMPARATO RR, et. al. Proton pump inhibitor deprescription: a rapid review. Brazilian Journal of Pharmaceutical Sciences, 2022; 58.
JAYNES M, KUMAR AB. The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic Advances in Drug Safety, 2019; 10.
LAM JR, et al. Uso de inibidor da bomba de prótons e antagonista do receptor de histamina 2 e deficiência de vitamina B12. JAMA, 2013; 310(22): 2435-2442.
LIMA JMD, et al. Uso do omeprazol: estudo descritivo de pacientes idosos de uma Unidade de Saúde da Família (USF) de Ribeirão Preto, SP, Brasil. Infarma-Ciências Farmacêuticas, 2019; 31(1): 46-53.
KIM SG, et al. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study. BMJ Open, 2024; 14(1).
LIAEBEUF S, et al. Resultados adversos dos inibidores da bomba de prótons em pacientes com doença renal crônica: o estudo de coorte CKD-REIN. British Journal of Clinical Pharmacology, 2021; 87(7): 2967–2976.
LAZARUS B, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Internal Medicine, 2016; 176(2): 238–246.
MAIDEEN NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Medical Journal, 2023; 59(2), 115.
MERTZ A, et al. Discontinuation of proton pump inhibitors in patients with chronic kidney disease. Hospital Pharmacy, 2021; 56(4): 308–313.
MORSCHEL CF, et al. The relationship between proton pump inhibitors and renal disease. Brazilian Journal of Nephrology, 2018; 40(3): 301–306.
NUGENT CC, et al. H2 blockers. StatPearls Publishing, 2023; 17 ago. Disponível em: www.ncbi.nlm.nih.gov/books/NBK525994. Acesso em: 5 fev. 2025.
PARMAR MP, et al. Impacto dos inibidores da bomba de prótons na função renal e na progressão da doença renal crônica: uma revisão sistemática. Cureus, 2023; 15(12): e49883.
PERAZELLA MA. Proton pump inhibitors and kidney disease: what gives? Kidney360, 2024; 3(7): 1137–1140.
RAJAN P, et al. Risk of bias in non-randomized observational studies assessing the relationship between proton-pump inhibitors and adverse kidney outcomes: a systematic review. Therapeutic Advances in Gastroenterology, 2022; 15.
SANTOS AS, et al. Kidney function decline associated with proton pump inhibitors: results from the ELSA-Brasil cohort. BMC Nephrology, 2023; 24(1).
SILVA MR, et al. Monteverdia ilicifolia: um protetor gástrico. Arquivos de Ciências da Saúde da UNIPAR, 2022; 26(3): 1248–1266.
SOUZA MNA, et al. Trilhando o caminho do conhecimento: o método de revisão integrativa para análise e síntese da literatura científica, 2023.Observatório de La Economía Latinoamericana, 2023; 21(10): 18448–18483
SHANIKA LGT, et al. Proton pump inhibitor use: systematic review of global trends and practices. European Journal of Clinical Pharmacology, 2023; 79(9): 1159–1172.
VEETTIL SK, et al. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. British Journal of Clinical Pharmacology, 2022; 88(4): 1551–1566.
VENGRUS CS, et al. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease. Minerva Urology and Nephrology, 2021; 73(4): 462–470
WEIR MR, et al. Inibidores da bomba de prótons e doença renal: fato ou ficção? American Journal of Nephrology, 2024; 55(4): 499–507.
WU B, et al. Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system. Scientific Reports, 2021; 11(1): 16979.
XIA B, et al. Individualized prevention of proton pump inhibitor related adverse events by risk stratification. Nature Communications, 2024; 15(1).
YIBIRIN M, et al. Adverse effects associated with proton pump inhibitor use. Cureus, 2021; 13(12): e12759.
YEPURI G, et al.Proton pump inhibitors accelerate endothelial senescence. Circulation Research, 2016; 118(12): e36-e42.
ZATERKA, S.; EISIG, JN Tratado de Gastroenterologia: da Graduação à Pós-Graduação. 2ª ed. São Paulo: Ateneu, 2016; 1.550p.